Log in

Oncorus Stock Forecast, Price & News

-0.10 (-0.60 %)
(As of 10/30/2020 12:00 AM ET)
Today's Range
Now: $16.61
50-Day Range N/A
52-Week Range
Now: $16.61
Volume71,418 shs
Average Volume101,681 shs
Market Capitalization$362.86 million
P/E RatioN/A
Dividend YieldN/A
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses to develop viral immunotherapies for cancer patients. Its lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform that it is in Phase I clinical trial to treat various cancers. The company is also developing ONCR-GBM program for treating brain cancer; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:ONCR



Sales & Book Value

Annual SalesN/A



Market Cap$362.86 million
Next Earnings DateN/A
OptionableNot Optionable
-0.10 (-0.60 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ONCR News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Oncorus (NASDAQ:ONCR) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Oncorus?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncorus in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Oncorus

What price target have analysts set for ONCR?

3 brokers have issued 1-year target prices for Oncorus' stock. Their forecasts range from $22.00 to $40.00. On average, they anticipate Oncorus' share price to reach $32.33 in the next twelve months. This suggests a possible upside of 94.7% from the stock's current price.
View analysts' price targets for Oncorus

Who are some of Oncorus' key competitors?

What other stocks do shareholders of Oncorus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncorus investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV), Axon Enterprise (AAXN) and Atlas Air Worldwide (AAWW).

Who are Oncorus' key executives?

Oncorus' management team includes the following people:
  • Dr. Theodore T. Ashburn, Pres, CEO & Director (Age 53)
  • Mr. John McCabe, CFO, Treasurer & Sec. (Age 50)
  • Mr. Christophe Quéva Ph.D., Chief Scientific Officer & Sr. VP of Research (Age 53)
  • Dr. John M. Goldberg M.D., Sr. VP of Clinical Devel. (Age 47)

When did Oncorus IPO?

(ONCR) raised $87 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 5,800,000 shares at $14.00-$16.00 per share. Jefferies, Evercore ISI and Piper Sandler acted as the underwriters for the IPO.

What is Oncorus' stock symbol?

Oncorus trades on the NASDAQ under the ticker symbol "ONCR."

When does Oncorus' quiet period expire?

Oncorus' quiet period expires on Wednesday, November 11th. Oncorus had issued 5,800,000 shares in its IPO on October 2nd. The total size of the offering was $87,000,000 based on an initial share price of $15.00. During Oncorus' quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Oncorus?

Shares of ONCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oncorus' stock price today?

One share of ONCR stock can currently be purchased for approximately $16.61.

How big of a company is Oncorus?

Oncorus has a market capitalization of $362.86 million. Oncorus employs 51 workers across the globe.

What is Oncorus' official website?

The official website for Oncorus is www.oncorus.com.

How can I contact Oncorus?

The company can be reached via phone at 857-320-6400.

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.